The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab.
Marlies Michl
No relevant relationships to disclose
Ludwig Fischer von Weikersthal
Other Remuneration - Roche
Alexander Crispin
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Alexander Kiani
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Tobias Heintges
No relevant relationships to disclose
Christian A. Lerchenmuller
No relevant relationships to disclose
Christoph Kahl
No relevant relationships to disclose
Gernot Seipelt
No relevant relationships to disclose
Frank Kullmann
No relevant relationships to disclose
Martina Stauch
No relevant relationships to disclose
Werner Scheithauer
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono; Roche
Joerg Hielscher
No relevant relationships to disclose
Michael Scholz
No relevant relationships to disclose
Sebastian Mueller
No relevant relationships to disclose
Dominik Paul Modest
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Amgen; Merck Serono; Roche
Other Remuneration - Amgen; Roche
Sebastian Stintzing
Consultant or Advisory Role - Bristol-Myers Squibb; Merck Serono; Roche/Genentech
Honoraria - Amgen; Merck Serono; Roche/Genentech; Sanofi
Other Remuneration - Merck Serono; Roche/Genentech
Volker Heinemann
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Roche
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Roche
Research Funding - Amgen; Merck Serono; Roche
Other Remuneration - Merck Serono